Reading a rodent study on a secretagogue without over-extrapolating — the long version

The bit of Reading a rodent study that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

Growth hormone secretagogues act on the ghrelin receptor or on the growth hormone releasing hormone receptor rather than supplying growth hormone, which is the distinction that matters for anyone reading the literature.

Post #16 answers the question as asked. The question underneath it is different.

On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.

Adding the caveat now so it does not have to be extracted later.

Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.

Post #27 is right about the mechanism and I think understates the practical bit.

Filing a mild objection to the consensus on Reading a rodent study. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

Taking post #41 at face value and following it one step further.

A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.

The reason Reading a rodent study keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.

Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.

Worth separating two things that post #59 runs together.

Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.

The rule of thumb is fine; the edge cases are where it earns its keep.